A solid phase, enzyme-linkcd immunoassay is described for the quantitative determination of the complex of human granulocyte elastase (EC 3.4.21.37) with αι-proteinase inhibitor. The assay employs antibody-coated test tubes and it is suitable for routine use in clinical chemistry laboratories. Data for sample stability and test characteristics are given. A reference r nge of 20-180 μg/l elastase in plasma was determined. The diagnostic significance of granulocyte elastase levels in plasma in inflammatory diseases is discussed.
Introduction
Human polymorphonuclear neutrophilic leukocytes contain large amounts of neutral proteinases which are released when the granulocyte? are exposed to a phagocytic Stimulus. In inflammatory diseases local imbalance between these proteinases and available proteinase inhibitors may cause tissue injury s well s degradation of plasma proteins (1) . Granulocyte elastase (EC 3.4.21.37) is of special pathological interest because of its high concentration and its broad specificity for a variety of connective tissue components (i.e. elastin, collagen, proteoglycans) and plasma proteins (i.e. IgG, complement factors €3 and' C 5 , various clotting factors), cf. I.e. (2, 3) . Clearly, the quantitative determination of elastase in in-flamed tissue and in the circulating blood should provide Information on connective tissue diseases, but only a few reports have so far been published on quantitative assays for the detection and quantitation of elastase in biological fluids (4) (5) (6) (7) 18) . The main inactivating agent in plasma for elastase is αι-proteinase inhibitor (8) . Elastase intcracts with the inhibitor to form a complex with a molar ratio of l to l and a molecular weight of approximatcly 80.000 Daltons (8) .
We developed a solid phase enzyme-linked immunoassay for the determination of the complex of elastase with αι-proteinase inhibitor (9, 10) . In this paper we describe a rapid assay version in test tubes for routine use in the clinical chemistry laboratory.
Materials and Methods

Reagents
All rcagents were from E. Merck, unless stated otherwise. Sepharose 6 B® and Concanavalin A-Sepharose® were from Deutsche Pharmacia; CM-Cellulose CM 52 was from Whatman Biochemicals Ltd; Methoxysuccinyl-L-ala-L-ala-L-pro-L-val-4-nitroanilide was from Bachern AG.
Granulocyte elastase and antibodies
Elastase was isolated from granule extracls of normal human granulocytes by a procedure described previously (11) . The preparation was free of contaminant granul r or serum proteins s shown by polyacrylamide gel electrophoresis at pH 4.5, and by immunoelectrophoresis with antisera against granul r extract and human serum.
Antisera against elastase were raised in sheep and were shown to be antigen-specific by immunoelectrophoresis. The immunoglobulin G fraction was isolated with the use of caprylic acid and ionexchange fractionation.
ai-Proteinase> inhibitor and antibodies
Human arproteinase inhibitor was isolated from outdated plasma. The purification procedure consisted of affinity chromatography on Fractogel® TSK-Red, ion exchange chromatography on Fractogel® TSK DEAE-650, and gel filtration on Fractogel® TSK HW-55 according to I.e. (12) . The resulting preparation of ar proteinase inhibitor was further purified by chromatography on Concanavalin A-Sepharose® (2.6 cm x 20 cm), previously equilibrated with 50 mmol/1 Tris/HCl buffer pH 7.5 containing l mmol/1 MgCh, l mmol MnCb, and l mmol/1 CaCb. Unbound material was washed from the column with the same buffer. ar Proteinase inhibitor was eiuted by adding 0.1 mol/1 methyl a-Dmannoside to the buffer. The final protein preparation was homogeneous s judged by a polyacrylamide gel electrophoresis at pH 9.0, and by immunoelectrophoresis. Antisera against oti-proteinase inhibitor were raised in rabbits and were shown to be antigen-specific by immunoelectrophoresis against human serum.
Coating Polystyrene tubes 10.5 x 40 mm (Greiner No. 655061) were coated by incubation with a solution containing 50 mg/1 antibodies against elastase in 10 mmol/1 ammonium hydrogen carbonate, pH 7.8, overnight at 4°C.
Preparation of labelled antibodies
Antibodies against arproteinase inhibitor were purified from rabbit antiserum, coupled to calf intestinal alkaline phosphatase by a one step glutaraldehyde procedure, and the labelled antibodies were isolated by gel filtration s described in a separate paper (13) .
.·,
Complex formation
The elastase/cti-proteinase inhibitor complex was produced by mixing elastase with an excess of the inhibitor. Elastase (0.5 mg) and αι-proteinase inhibitor (2.8 mg) were incubated fof 30 min at 37 °C in 2 ml 30 mmol/1 tris(hydroxymethyl)aminomethane/HCl buffer pH 8.0, containing 85 mmol/1 NaCl. Under these condl· tions elastase is totally inactivated by complex formation s shown by assay of the catalytic ctivity using methoxysuccinyl-L-aia-Lala-L-pro-L-val-4-nitroanilide (14), immunoelectrophoresis and polyacrylamide gel electrophoresis at pH 4.3.
The immunoassay
The assay principle is given in figure 1.
Step l Dilute one volume of plasma with 50 Volumes of phosphate-buffered saline containing 10 g/l bovine serum albumin and 20 mmol/1 EDTA.
Step 2 Incubate 500 μΐ sample diluent, Standard or diluted sample per tube l h at room temperature.
Step 3 Wash three times with distilled water containing 0.5 g/l polyoxyethylene sorbitan monolaurate.
Step 4 Incubate with 500 μΐ reagent containing alkaline phosphatase labelled rabbit-IgG against arproteinase inhibitor l h at room temperature.
Step 5 Wash once with distilled water containing 0.5 g/l polyoxyethylene sorbitan monolaiirate.
Step 6 Incubate with 500 μΐ 10 mmol/1 4-nitfophenyl phosphate in l mol/1 diethanolamine/HCl-buffer pH 9.8 containing 0.5 mmol/1 MgCJ 2 .
Step 7 Stop enzyme reaction by adding 500 μΐ 2 mol/1 NaOH.
Step 8 Read absorbance at 405 nm. Standard Solutions with defined levels of complexed elastase were prepared by diluting the reaction mixture with phosphate-buffered saline containing 10 g/l bovine serum albumin. Control plasma with a known level of the complex was produced s follows: Citrated plasma from non-immunized sheep was inactivated at 56 °C for 45 min and mixed with a defined amount of elastase-ar proteinase inhibitor complex.
Detection limit
The lower limit of sensitivity, s defined by the mean absorbance of the blanks plus three Standard deviations, was 0.25 ng per test tube. The detection limit was increased by increasing the reaction periods in
Step 2 and Step 4 of the assay (see section "The immunoassay").
Sample collection
Citrated or EDTA plasma was used. Plasma was separated from blood within 30 min after sample collection to prevent interference by in vitro secretion by leukocytes (15, 16) . Tests were performed either on fresh plasma or on aliquots stored frozen at -20 °C or -70 °C.
Precision
Precision was monitored with different plasma pools (tab. 1). Within-run imprecision (coefficient of Variation) was 4 to 8%, and between-run imprecision was in the r nge of 3 to 8% CV.
Results
Standard curve
The absorbance values obtained with sample diluent and the Standard Solutions were plotted versus concentration on a linear diagram ( fig. 2) . The intercept at 0 μg/l and the slope were calculated by linear regression. Absorbance readings from unknown samples were referred to the calibration curve.
The working r nge of the assay is 0.5 to 5.0 ng of elastase in complex with αι-proteinase inhibitor in the assay tube. This is equal to a r nge of 51 to 510 μg/l in plasma when testing plasma samples diluted l -f 50 in 500 μΐ final volume. Elastase I/xg/ll 
Sample stability
Citrated plasma was stored at least 6 months at -20°C or 14 days at +2°C to +8°C without appreciable loss of the antigenic reactivity of the elastase/arproteinase inhibitor complex.
Linearity and parallelity
Citrated plasmas were pooled to give a plasma specimen with levels of 60 or 500 μg/l of complexed elastase. Linear results were obtained with plasma samples of 10 to 80 μΐ from the first pool, and with plasma samples of l to 8 μΐ from the second pool. The slopes of the plasma dilution curves were not significantly different from that of the calibration curve ( fig. 3) . 
Recovery
Aliquots of the elastase/ai-proteinase inhibitor complex s produced in vitro were added to six different citrated human plasma samples. The concentrations of the complex in the native and the spiked plasma samples were assayed. Recovery was 75 to 96 percent.
Plasma reference r nge
The plasma concentration of the elastase/cxj-proteinase inhibitor complex was measured in citrated plasma from 172 randomly selected, apparently healthy laboratory workers. The group consisted of 165 males and 7 females, age r nge 18 to 62 years. The concentration of complexed elastase was in the r nge 20 to 180 μ£/1 with a mean ± Standard deviation of 67 ± 31 μg/l and a median of 64
Discussion
In recent years evidence has accumulated for the role of granulocyte elastase s a main pathogenetical factor in inflammatory processes. However, only a few reports have appeared on the development of quantitative laboratory assays for the deterrnination of granulocyte elastase levels in plasma or other biological fluids. The immunoassays for granulocytic elastase reported so far are electroimmunodiffusion (4), radioimmunoassay (5, 7) and a competitive enzyme-linked immunoassay for canine granulocytic elastase (6) . These determination techniques for elastase have riot found wide application in the clinical chemistry laboratory.
In previous reports it was shown that granulocyte elastase in plasma is complexed mainly with ai-proteinase inhibitor (8, 17) . Elastase in this complex is devoid of enzymatic activity. A small fraction of the enzyme is also bound to oto-macroglobulin (8) . Granulocyte elastase in this complex retains some enzymatic activity towards a peptide Substrate (14) . Determination of this activity in plasma does not appear to be a sensitive parameter for granulocyte elastase, because the elastase/o^macroglobulin complex represents only a small fraction of the elastase molecules present in plasma and is elirninated very quickly from the circulation (17) . We chose an alternative approach, i.e. the irnmunochemical quantitation of the plasma concentration of the complex of elastase with αι-proteinase inhibitor. This technique rnakes use of the dual immunological specificity of the equimolar complex of an enzyme firmly bound to its inhibitor. In a first assay version microculture plates were used s carriers for the antibodies against elastase (9, 10). A similar assay which is based on the same principle was recently,,reported by another group (18) . However, in our view, it is more convenient to use volumes of 0.5 or 1.0 ml for absorption readings on routine photometers. We therefore developed a version of the assay^ which employs polystyrene tubes, and the characteristics of this assay are reported here. Both detection limits, withinseries and between-series imprecision, linearity, parallelity of calibrators and plasma dilutions and recovery are within reasonable limits. Our method is sensitive, precise and practicable with the equipment of a routine clinical chemistry laboratory.
A normal r nge of 20 to 180 μg/l was found in a group of healthy laboratory workers. Work in .progress will define the reference r nge on different and enlarged normal groups.
In preliminary clinical studies largely increased plasma levels were found in patients with septicaemia, polytrauma and in most patients with acute rheumatoid arthritis (3, 19, 20, 21) . These data suggest a diagnostic relevance of granulocyte elastase levels in plasma.
